Phase I Trial of Triapine (Ribonucleotide Reductase Inhibitor) with Radiation for Recurrent Gliomas

This study evaluates the safety, side effects, and optimal dose of triapine in combination with daily intensity modulated radiation therapy for patients with recurrent diffuse midline gliomas, astrocytomas (IDH-mutant), or glioblastomas (IDH-wildtype). Triapine, a ribonucleotide reductase inhibitor, is given orally two hours prior to radiation treatment, with imaging and biospecimen assessments monitoring response. The trial is sponsored by the National Cancer Institute.